Uriach strategic transformation is beginning to show results

Uriach Group EBITDA grew by 100% compared to the previous year, going from 10 to 20 million euros. This was achieved by aligning the activity of its four strategic business areas: OTC and Natural Care, Generics, Pharma Licensing and Contract Manufacturing.

Grupo Uriach presents its new Board of Directors

The company has named Joaquín Uriach to be its new president,
and has announced the additions of Francisco Belil and Marta Uriach

Oriol Segarra joins Grupo Uriach as CEO

  Oriol Segarra joins Grupo Uriach as CEO Grupo Uriach has named Oriol Segarra Montaner to be the new Chief Executive Officer. Tomorrow, he will officially begin carrying out duties as the main... [leer más]